RESUMEN
Human physiology is regulated by endogenous signalling compounds, including fatty acid amides (FAAs), chemical mimics of which are made by bacteria. The molecules produced by human-associated microbes are difficult to identify because they may only be made in a local niche or they require a substrate sourced from the host, diet or other microbes. We identified a set of uncharacterized gene clusters in metagenomics data from the human gut microbiome. These clusters were discovered to make FAAs by fusing exogenous fatty acids with amines. Using an in vitro assay, we tested their ability to incorporate 25 fatty acids and 53 amines known to be present in the human gut, from which the production of six FAAs was deduced (oleoyl dopamine, oleoyl tyramine, lauroyl tryptamine, oleoyl aminovaleric acid, α-linolenoyl phenylethylamine and caproyl tryptamine). These molecules were screened against panels of human G-protein-coupled receptors to deduce their putative human targets. Lauroyl tryptamine is found to be an antagonist to the immunomodulatory receptor EBI2 against its native oxysterol ligand (0.98 µM half-maximal inhibitory concentration), is produced in culture by Eubacterium rectale and is present in human faecal samples. FAAs produced by Clostridia may serve as a mechanism to modulate their host by mimicking human signalling molecules.
Asunto(s)
Aminas/metabolismo , Ácidos Grasos/metabolismo , Firmicutes/metabolismo , Microbioma Gastrointestinal , Neurotransmisores/metabolismo , Aminas/química , Dieta , Ácidos Grasos/química , Firmicutes/clasificación , Firmicutes/genética , Tracto Gastrointestinal/metabolismo , Tracto Gastrointestinal/microbiología , Humanos , Neurotransmisores/química , Receptores Acoplados a Proteínas G/genética , Receptores Acoplados a Proteínas G/metabolismo , Transducción de SeñalRESUMEN
Chemogenetic libraries, collections of well-defined chemical probes, provide tremendous value to biomedical research but require substantial effort to ensure diversity as well as quality of the contents. We have assembled a chemogenetic library by data mining and crowdsourcing institutional expertise. We are sharing our approach, lessons learned, and disclosing our current collection of 4,185 compounds with their primary annotated gene targets (https://github.com/Novartis/MoaBox). This physical collection is regularly updated and used broadly both within Novartis and in collaboration with external partners.
Asunto(s)
Sondas Moleculares/química , Bibliotecas de Moléculas Pequeñas/química , Bioensayo , Bases de Datos de Compuestos Químicos , Descubrimiento de Drogas , Humanos , Aprendizaje Automático , Sondas Moleculares/metabolismo , Bibliotecas de Moléculas Pequeñas/metabolismoRESUMEN
Herein we demonstrate that a small panel of variants of cytochrome P450 BM3 from Bacillus megaterium covers the breadth of reactivity of human P450s by producing 12 of 13 mammalian metabolites for two marketed drugs, verapamil and astemizole, and one research compound. The most active enzymes support preparation of individual metabolites for preclinical bioactivity and toxicology evaluations. Underscoring their potential utility in drug lead diversification, engineered P450 BM3 variants also produce novel metabolites by catalyzing reactions at carbon centers beyond those targeted by animal and human P450s. Production of a specific metabolite can be improved by directed evolution of the enzyme catalyst. Some variants are more active on the more hydrophobic parent drug than on its metabolites, which limits production of multiply-hydroxylated species, a preference that appears to depend on the evolutionary history of the P450 variant.
Asunto(s)
Sistema Enzimático del Citocromo P-450/metabolismo , Preparaciones Farmacéuticas/metabolismo , Astemizol/química , Astemizol/metabolismo , Bacillus megaterium/enzimología , Biocatálisis , Dominio Catalítico , Cromonas/química , Cromonas/metabolismo , Sistema Enzimático del Citocromo P-450/genética , Evolución Molecular , Humanos , Morfolinas/química , Morfolinas/metabolismo , Mutagénesis Sitio-Dirigida , Proteínas Recombinantes de Fusión/genética , Proteínas Recombinantes de Fusión/metabolismo , Verapamilo/química , Verapamilo/metabolismoRESUMEN
Classifying kinases based entirely on small molecule selectivity data is a new approach to drug discovery that allows scientists to understand relationships between targets. This approach combines the understanding of small molecules and targets, and thereby assists the researcher in finding new targets for existing molecules or understanding selectivity and polypharmacology of molecules in related targets. Currently, structural information is available for relatively few of the protein kinases encoded in the human genome (7% of the estimated 518); however, even the current knowledge base, when paired with structure-based design techniques, can assist in the identification and optimization of novel kinase inhibitors across the entire protein class. Chemogenomics attempts to combine genomic data, structural biological data, classical dendrograms, and selectivity data to explore, define, and classify the medicinally relevant kinase space. Exploitation of this information in the discovery of kinase inhibitors defines practical kinase chemogenomics (kinomics). In this paper, we review the available information on kinase targets and their inhibitors, and present the relationships between the various classification schema for kinase space. In particular, we present the first dendrogram of kinases based entirely on small molecule selectivity data. We find that the selectivity dendrogram differs from sequence-based clustering mostly in the higher-level groupings of the smaller clusters, and remains very comparable for closely homologous targets. Highly homologous kinases are, on average, inhibited comparably by small molecules. This observation, although intuitive, is very important to the process of target selection, as one would expect difficulty in achieving inhibitor selectivity for kinases that share high sequence identity.
Asunto(s)
Diseño de Fármacos , Inhibidores Enzimáticos/química , Inhibidores Enzimáticos/farmacología , Fosfotransferasas/antagonistas & inhibidores , Fosfotransferasas/genética , Adenosina Trifosfato/metabolismo , Sitios de Unión , Análisis por Conglomerados , Biología Computacional/métodos , Bases de Datos Factuales , Genómica/métodos , Humanos , Modelos Moleculares , Estructura Molecular , Fosfotransferasas/metabolismo , Relación Estructura-ActividadRESUMEN
Chlorogenic acid derivatives are potent inhibitors of hepatic glucose production by inhibition of the glucose-6-phosphate translocase component of the hepatic glucose-6-phosphatase system. The pharmacological proof of concept was clearly demonstrated during i.v. infusion of potent derivatives (S 4048, S 3483) in rats. However, the blood glucose lowering effect of S 4048 after bolus i.v. injection lasted only 60-90 min. Plasma clearance of S 4048 was very high, and the parent compound was rapidly and efficiently excreted into the bile of Wistar and GY/TR(-) rats, indicating that mrp-2 was not involved in this hepatobiliary elimination process. About 72% of the total administered radioactivity appeared in the bile within 20 min after i.v. bolus injection of the radiolabeled analogue [(3)H]S 1743 in a Wistar rat. However, in GY/TR(-) rats the dicarboxylic analogue of S 4048, S 3025, was cleared from the plasma less rapidly than its parent compound and its biliary elimination was comparatively low. In contrast, S 3025 exhibited comparable pharmacokinetics and biliary elimination profile as S 4048 in Wistar rats, suggesting that biliary elimination of S 3025 is facilitated by mrp-2, functionally absent in GY/TR(-) rats. Targeting to mrp-2 resulted in a significantly prolonged reduction of blood glucose levels in GY/TR(-) rats after i.v. bolus administration of S 3025.
Asunto(s)
Glucemia/análisis , Citocinas/deficiencia , Imidazoles/farmacocinética , Proteínas Inflamatorias de Macrófagos , Fosfotransferasas/antagonistas & inhibidores , Piridinas/farmacocinética , Animales , Antiportadores , Bilis/metabolismo , Quimiocinas CC , Regulación hacia Abajo , Inhibidores Enzimáticos/farmacocinética , Infusiones Intravenosas , Estructura Molecular , Proteínas de Transporte de Monosacáridos , Ratas , Ratas Wistar , TritioRESUMEN
The voltage-gated potassium channel Kv1.5 is regarded as a promising target for the development of new atrial selective drugs with fewer side effects. In the present study the discovery of ortho,ortho-disubstituted bisaryl compounds as blockers of the Kv1.5 channel is presented. Several compounds of this new class were synthesized and screened for their ability to block Kv1.5 channels expressed in Xenopus oocytes. The observed structure-activity relationship (SAR) is described by a pharmacophore model that consists of three hydrophobic centers in a triangular arrangement. The hydrophobic centers are matched by a phenyl or pyridyl ring of the bisaryl core and both ends of the side chains. The most potent compounds (e.g., 17c and 17o) inhibited the Kv1.5 channel with sub-micromolar half-blocking concentrations and displayed 3-fold selectivity over Kv1.3 and no significant effect on the HERG channel and sodium currents. In addition, compounds 17c and 17m have already shown antiarrhythmic effects in a pig model.
Asunto(s)
Antiarrítmicos/síntesis química , Compuestos de Bifenilo/síntesis química , Bloqueadores de los Canales de Potasio/síntesis química , Canales de Potasio con Entrada de Voltaje , Canales de Potasio/efectos de los fármacos , Piridinas/síntesis química , Animales , Antiarrítmicos/química , Antiarrítmicos/farmacología , Compuestos de Bifenilo/química , Compuestos de Bifenilo/farmacología , Humanos , Técnicas In Vitro , Activación del Canal Iónico , Canal de Potasio Kv1.5 , Modelos Moleculares , Oocitos/efectos de los fármacos , Oocitos/fisiología , Técnicas de Placa-Clamp , Bloqueadores de los Canales de Potasio/química , Bloqueadores de los Canales de Potasio/farmacología , Canales de Potasio/fisiología , Piridinas/química , Piridinas/farmacología , Relación Estructura-Actividad , Xenopus laevisRESUMEN
This article describes our experiences in creating a fully integrated, globally accessible, automated chemical synthesis laboratory. The goal of the project was to establish a fully integrated automated synthesis solution that was initially focused on minimizing the burden of repetitive, routine, rules-based operations that characterize more established chemistry workflows. The architecture was crafted to allow for the expansion of synthetic capabilities while also providing for a flexible interface that permits the synthesis objective to be introduced and manipulated as needed under the judicious direction of a remote user in real-time. This innovative central synthesis suite is herein described along with some case studies to illustrate the impact such a system is having in expanding drug discovery capabilities.
Asunto(s)
Descubrimiento de Drogas/organización & administración , Arquitectura y Construcción de Instituciones de Salud , Laboratorios/organización & administración , Preparaciones Farmacéuticas/síntesis química , Robótica/organización & administración , Tecnología Farmacéutica/organización & administración , Automatización de Laboratorios , Equipos Desechables , Descubrimiento de Drogas/métodos , Descubrimiento de Drogas/normas , Eficiencia Organizacional , Arquitectura y Construcción de Instituciones de Salud/normas , Laboratorios/normas , Innovación Organizacional , Preparaciones Farmacéuticas/normas , Robótica/normas , Diseño de Software , Tecnología Farmacéutica/métodos , Tecnología Farmacéutica/normas , Interfaz Usuario-Computador , Flujo de TrabajoRESUMEN
The search for novel, potent Kv1.5 blockers based on an anthranilic amide scaffold employing a pharmacophore-based virtual screening approach is described. The synthesis and structure-activity relationships (SAR) with respect to inhibition of the Kv1.5 channel are discussed. The most potent compounds display sub-micromolar inhibition of Kv1.5 and no significant effect on the HERG channel. In addition, good oral bioavailability is demonstrated for compound 3i in rats.